Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin-6 receptor subunit alpha (IL6R), also known as CD126, is a type I cytokine receptor and forms part of the functional IL-6 receptor complex. It binds interleukin 6 (IL‑6) with low affinity; signal transduction requires association with gp130/IL‑6ST. IL6R exists in both membrane-bound and soluble forms. It regulates immune response, acute-phase reactions, hematopoiesis, cell growth/differentiation, and tissue regeneration and is implicated in multiple diseases including autoimmune diseases and cancer. Therapeutic targeting includes monoclonal antibodies and small molecule antagonists.
Monoclonal antibody or small molecule antagonist binding to IL-6R, blocking IL-6 signaling and subsequent downstream pathway activation, such as JAK/STAT
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-6 Receptor Subunit Alpha (IL6R).